Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors

International Journal of Cardiology

Volumn 146, Issue 2, 2011, Pages 280-282

  Lin, Gen Min ^a,b   Chu, Kai Min ^a   Han, Chih Lu ^c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Acute ST segment elevation myocardial infarction; Glycoprotein IIb IIIa Inhibitor; Pexelizumab; Primary percutaneous coronary intervention

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; PEXELIZUMAB; PLACEBO; THIENOPYRIDINE DERIVATIVE;

DRUG SAFETY; HUMAN; LETTER; MATHEMATICAL MODEL; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 78651422977     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.085     Document Type: Article

References (12)

1. A.P. Vakeva, A. Agah, and S.A. Rollins Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy Circulation 97 1998 2259 2267
2. C.B. Granger, K.W. Mahaffey, and W.D. Weaver Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial Circulation 108 2003 1184 1190
3. E.D. Verrier, S.K. Shernan, and K.M. Taylor Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial JAMA 291 2004 2319 2327
4. K.W. Mahaffey, C.B. Granger, and J.C. Nicolau Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial Circulation 108 2003 1176 1183
5. APEX AMI Investigators, Armstrong P.W., and Granger C.B. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
6. K. Huber, D.R. Holmes Jr., and A.W. van 't Hof Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial Eur Heart J 31 2010 1708 1716
7. G.M. Lin, and C.L. Han Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials Eur Heart J 31 2010 753 754
8. G.W. Stone, C.L. Grines, and D.A. Cox Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction N Engl J Med 346 2002 957 966
9. Van't Hof A.W., Ten Berg J., and Heestermans T. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial Lancet 372 2008 537 546
10. S.G. Ellis, M. Tendera, and M.A. de Belder Facilitated PCI in patients with ST-elevation myocardial infarction N Engl J Med 358 2008 2205 2217
11. Røger M., Høgåsen K., and Holme P.A. The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation Platelet 6 1995 160 168
12. Coats A.J. Ethical authorship and publishing Int J Cardiol 131 2009 149 150